Aesthetic device company Candela and medical device manufacturer InMode have entered into a worldwide comprehensive mutual settlement agreement, ending patent disputes between the companies.
In January 2016, Candela presented InMode with patent infringement suits concerning its Sublative Technology. Promoted as an anti-ageing treatment, Sublative Technology uses fractionated bipolar radiofrequency to generate deep dermal heating and elicit a wound-healing response for tightening and rejuvenating the skin, Candela claim.
The settlement took place in San Francisco, California, and through a sublicense provided by Candela, InMode are permitted to continue to market its bi-polar fractional radiofrequency product line, which includes the Fractora and the Morpheus8 devices, protecting Candela’s investment in the development of long-pulse laser devices.
Geoffrey Crouse, CEO of Candela, commented, “We are pleased to have reached a settlement with InMode on mutually-agreeable terms.” Moshe Mizrahy, co-founder and CEO of InMode, added, “We look forward to moving on and fulfilling our mandate of launching advanced solutions for doctors and clinics worldwide.”
Terms of the settlement agreement were not disclosed.